Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IcoSema vs insulin icodec in type 2 diabetes on basal insulin
NCT05352815Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2022
- Primary completion
- Mar 2024
- Modality
- Peptides
- Countries
- 22
01
Overview
A Phase 3 trial of icosema in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jun 2022; status: completed.
02
Drugs
icosema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05352815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352815.